RESEARCH ARTICLE A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa 1,2 3,4 1 2 David Ruano-GallegoID , Daniel A. YaraID , Lorenza Di IanniID , Gad Frankel , 3,4 1 Stephanie SchuÈ llerID , Luis AÂ ngel FernaÂndezID * a1111111111 1 Department of Microbial Biotechnology, Centro Nacional de BiotecnologõÂa, Consejo Superior de Investigaciones CientõÂficas (CSIC), Campus UAM-Cantoblanco, Madrid, Spain, 2 MRC Centre for Molecular a1111111111 Bacteriology and Infection, Life Sciences Department, Imperial College London, London, United Kingdom, a1111111111 3 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom, a1111111111 4 Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom a1111111111 *
[email protected] Abstract OPEN ACCESS Citation: Ruano-Gallego D, Yara DA, Di Ianni L, Enterohemorrhagic E. coli (EHEC) is a human intestinal pathogen that causes hemorrhagic Frankel G, SchuÈller S, FernaÂndez LAÂ (2019) A colitis and hemolytic uremic syndrome. No vaccines or specific therapies are currently avail- nanobody targeting the translocated intimin able to prevent or treat these infections. EHEC tightly attaches to the intestinal epithelium by receptor inhibits the attachment of injecting the intimin receptor Tir into the host cell via a type III secretion system (T3SS). In enterohemorrhagic E. coli to human colonic mucosa. PLoS Pathog 15(8): e1008031. https:// this project, we identified a camelid single domain antibody (nanobody), named TD4, that doi.org/10.1371/journal.ppat.1008031 recognizes a conserved Tir epitope overlapping the binding site of its natural ligand intimin Editor: Brian K. Coombes, McMaster University, with high affinity and stability.